MAPT and Alzheimer disease: In order to assist researchers in targeting the biology underlying AD rather than the symptoms of dementia, a biologically based research framework has been developed, which relies on biomarkers sensitive to the aggregated Aβ (A), aggregated tau (T), and neurodegeneration or neuronal injury (N) (AT(N) scale) [6].